nodes	percent_of_prediction	percent_of_DWPC	metapath
Sunitinib—kidney cancer—testicular cancer	0.341	1	CtDrD
Sunitinib—STK11—testicular cancer	0.162	0.437	CbGaD
Sunitinib—STK10—testicular cancer	0.153	0.414	CbGaD
Sunitinib—KIT—testicular cancer	0.0549	0.149	CbGaD
Sunitinib—ABCG2—Dactinomycin—testicular cancer	0.00787	0.0808	CbGbCtD
Sunitinib—CYP3A7-CYP3A51P—Ifosfamide—testicular cancer	0.00686	0.0705	CbGbCtD
Sunitinib—CYP3A7—Ifosfamide—testicular cancer	0.00686	0.0705	CbGbCtD
Sunitinib—ABCC2—Carboplatin—testicular cancer	0.00585	0.0601	CbGbCtD
Sunitinib—ABCC4—Methotrexate—testicular cancer	0.00546	0.056	CbGbCtD
Sunitinib—ABCC2—Vinblastine—testicular cancer	0.00545	0.056	CbGbCtD
Sunitinib—ABCG2—Carboplatin—testicular cancer	0.00529	0.0543	CbGbCtD
Sunitinib—CYP3A5—Ifosfamide—testicular cancer	0.00515	0.0529	CbGbCtD
Sunitinib—ABCC2—Cisplatin—testicular cancer	0.005	0.0513	CbGbCtD
Sunitinib—ABCC2—Etoposide—testicular cancer	0.00491	0.0504	CbGbCtD
Sunitinib—ABCG2—Cisplatin—testicular cancer	0.00452	0.0464	CbGbCtD
Sunitinib—ABCG2—Etoposide—testicular cancer	0.00444	0.0456	CbGbCtD
Sunitinib—ABCC2—Doxorubicin—testicular cancer	0.00335	0.0344	CbGbCtD
Sunitinib—ABCC2—Methotrexate—testicular cancer	0.00325	0.0333	CbGbCtD
Sunitinib—ABCG2—Doxorubicin—testicular cancer	0.00303	0.0311	CbGbCtD
Sunitinib—ABCG2—Methotrexate—testicular cancer	0.00293	0.0301	CbGbCtD
Sunitinib—ABCB1—Dactinomycin—testicular cancer	0.00284	0.0291	CbGbCtD
Sunitinib—CYP3A5—Etoposide—testicular cancer	0.00246	0.0253	CbGbCtD
Sunitinib—CYP3A4—Ifosfamide—testicular cancer	0.00201	0.0206	CbGbCtD
Sunitinib—ABCB1—Vinblastine—testicular cancer	0.00178	0.0183	CbGbCtD
Sunitinib—ABCB1—Cisplatin—testicular cancer	0.00163	0.0167	CbGbCtD
Sunitinib—ABCB1—Etoposide—testicular cancer	0.0016	0.0164	CbGbCtD
Sunitinib—ABCB1—Doxorubicin—testicular cancer	0.00109	0.0112	CbGbCtD
Sunitinib—CYP3A4—Vinblastine—testicular cancer	0.00107	0.0109	CbGbCtD
Sunitinib—ABCB1—Methotrexate—testicular cancer	0.00106	0.0109	CbGbCtD
Sunitinib—CYP3A4—Etoposide—testicular cancer	0.00096	0.00985	CbGbCtD
Sunitinib—CYP3A4—Doxorubicin—testicular cancer	0.000655	0.00672	CbGbCtD
Sunitinib—STK24—Teniposide—Etoposide—testicular cancer	0.000289	0.167	CbGdCrCtD
Sunitinib—PLK4—testis—testicular cancer	0.000133	0.00209	CbGeAlD
Sunitinib—STK4—testis—testicular cancer	0.000132	0.00207	CbGeAlD
Sunitinib—STK3—female gonad—testicular cancer	0.000132	0.00206	CbGeAlD
Sunitinib—RPS6KA5—lymph node—testicular cancer	0.000132	0.00206	CbGeAlD
Sunitinib—ROCK1—female gonad—testicular cancer	0.00013	0.00204	CbGeAlD
Sunitinib—PHKG2—testis—testicular cancer	0.00013	0.00204	CbGeAlD
Sunitinib—KDR—embryo—testicular cancer	0.00013	0.00203	CbGeAlD
Sunitinib—STK24—testis—testicular cancer	0.000129	0.00203	CbGeAlD
Sunitinib—CHEK2—Vindesine—Vinblastine—testicular cancer	0.000129	0.0744	CbGdCrCtD
Sunitinib—DAPK2—testis—testicular cancer	0.000128	0.002	CbGeAlD
Sunitinib—MAP2K2—gonad—testicular cancer	0.000127	0.00199	CbGeAlD
Sunitinib—ULK3—gonad—testicular cancer	0.000127	0.00199	CbGeAlD
Sunitinib—DYRK1A—female gonad—testicular cancer	0.000127	0.00199	CbGeAlD
Sunitinib—CSF1R—embryo—testicular cancer	0.000127	0.00198	CbGeAlD
Sunitinib—CLK4—lymph node—testicular cancer	0.000127	0.00198	CbGeAlD
Sunitinib—MAP3K2—gonad—testicular cancer	0.000126	0.00198	CbGeAlD
Sunitinib—STK16—testis—testicular cancer	0.000126	0.00197	CbGeAlD
Sunitinib—HIPK3—testis—testicular cancer	0.000125	0.00196	CbGeAlD
Sunitinib—HIPK2—testis—testicular cancer	0.000125	0.00196	CbGeAlD
Sunitinib—TYRO3—testis—testicular cancer	0.000125	0.00196	CbGeAlD
Sunitinib—ALK—testis—testicular cancer	0.000125	0.00196	CbGeAlD
Sunitinib—ITK—lymph node—testicular cancer	0.000125	0.00196	CbGeAlD
Sunitinib—SBK1—lymph node—testicular cancer	0.000125	0.00196	CbGeAlD
Sunitinib—MERTK—female gonad—testicular cancer	0.000124	0.00194	CbGeAlD
Sunitinib—TNK1—testis—testicular cancer	0.000124	0.00194	CbGeAlD
Sunitinib—RIOK2—testis—testicular cancer	0.000124	0.00194	CbGeAlD
Sunitinib—TBK1—gonad—testicular cancer	0.000124	0.00194	CbGeAlD
Sunitinib—BLK—lymph node—testicular cancer	0.000124	0.00194	CbGeAlD
Sunitinib—MAP3K19—testis—testicular cancer	0.000123	0.00192	CbGeAlD
Sunitinib—MAP4K1—testis—testicular cancer	0.000123	0.00192	CbGeAlD
Sunitinib—DAPK1—lymph node—testicular cancer	0.000122	0.00192	CbGeAlD
Sunitinib—PHKG1—lymph node—testicular cancer	0.000122	0.00192	CbGeAlD
Sunitinib—KDR—seminal vesicle—testicular cancer	0.000122	0.00191	CbGeAlD
Sunitinib—MAP2K5—seminal vesicle—testicular cancer	0.000122	0.00191	CbGeAlD
Sunitinib—MAP4K4—female gonad—testicular cancer	0.000122	0.00191	CbGeAlD
Sunitinib—NUAK2—female gonad—testicular cancer	0.000121	0.00189	CbGeAlD
Sunitinib—DAPK3—testis—testicular cancer	0.00012	0.00188	CbGeAlD
Sunitinib—FLT3—female gonad—testicular cancer	0.00012	0.00188	CbGeAlD
Sunitinib—MAP3K12—female gonad—testicular cancer	0.00012	0.00188	CbGeAlD
Sunitinib—CLK2—testis—testicular cancer	0.000119	0.00187	CbGeAlD
Sunitinib—CSF1R—seminal vesicle—testicular cancer	0.000119	0.00186	CbGeAlD
Sunitinib—MAP4K2—testis—testicular cancer	0.000119	0.00186	CbGeAlD
Sunitinib—BRD4—lymph node—testicular cancer	0.000118	0.00185	CbGeAlD
Sunitinib—STK11—lymph node—testicular cancer	0.000118	0.00185	CbGeAlD
Sunitinib—RPS6KA3—female gonad—testicular cancer	0.000118	0.00185	CbGeAlD
Sunitinib—AXL—gonad—testicular cancer	0.000118	0.00185	CbGeAlD
Sunitinib—MAP2K1—female gonad—testicular cancer	0.000117	0.00184	CbGeAlD
Sunitinib—RPS6KA1—lymph node—testicular cancer	0.000117	0.00184	CbGeAlD
Sunitinib—RIOK1—lymph node—testicular cancer	0.000117	0.00184	CbGeAlD
Sunitinib—STK3—testis—testicular cancer	0.000117	0.00183	CbGeAlD
Sunitinib—CSNK1A1—female gonad—testicular cancer	0.000116	0.00182	CbGeAlD
Sunitinib—ROCK1—testis—testicular cancer	0.000115	0.00181	CbGeAlD
Sunitinib—CLK1—female gonad—testicular cancer	0.000115	0.0018	CbGeAlD
Sunitinib—KIT—embryo—testicular cancer	0.000115	0.0018	CbGeAlD
Sunitinib—MARK2—lymph node—testicular cancer	0.000115	0.0018	CbGeAlD
Sunitinib—TNIK—lymph node—testicular cancer	0.000115	0.0018	CbGeAlD
Sunitinib—SGK3—lymph node—testicular cancer	0.000114	0.00178	CbGeAlD
Sunitinib—BMP2K—female gonad—testicular cancer	0.000113	0.00177	CbGeAlD
Sunitinib—CAMK2G—female gonad—testicular cancer	0.000113	0.00177	CbGeAlD
Sunitinib—ICK—lymph node—testicular cancer	0.000113	0.00177	CbGeAlD
Sunitinib—DYRK1A—testis—testicular cancer	0.000113	0.00176	CbGeAlD
Sunitinib—PDGFRB—embryo—testicular cancer	0.000112	0.00176	CbGeAlD
Sunitinib—LRRK2—female gonad—testicular cancer	0.000112	0.00176	CbGeAlD
Sunitinib—JAK2—gonad—testicular cancer	0.000112	0.00175	CbGeAlD
Sunitinib—PRKAA1—female gonad—testicular cancer	0.00011	0.00173	CbGeAlD
Sunitinib—MERTK—testis—testicular cancer	0.00011	0.00172	CbGeAlD
Sunitinib—PTK2B—female gonad—testicular cancer	0.000109	0.00171	CbGeAlD
Sunitinib—CHEK2—lymph node—testicular cancer	0.000109	0.00171	CbGeAlD
Sunitinib—NUAK1—lymph node—testicular cancer	0.000109	0.00171	CbGeAlD
Sunitinib—FLT4—female gonad—testicular cancer	0.000109	0.00171	CbGeAlD
Sunitinib—INSR—lymph node—testicular cancer	0.000108	0.00169	CbGeAlD
Sunitinib—OXSR1—lymph node—testicular cancer	0.000108	0.00169	CbGeAlD
Sunitinib—SNRK—lymph node—testicular cancer	0.000108	0.00169	CbGeAlD
Sunitinib—KIT—seminal vesicle—testicular cancer	0.000108	0.00169	CbGeAlD
Sunitinib—MAP4K4—testis—testicular cancer	0.000108	0.00169	CbGeAlD
Sunitinib—MAP4K5—gonad—testicular cancer	0.000108	0.00169	CbGeAlD
Sunitinib—MAP3K3—gonad—testicular cancer	0.000108	0.00169	CbGeAlD
Sunitinib—CSNK1E—female gonad—testicular cancer	0.000107	0.00168	CbGeAlD
Sunitinib—FGFR1—female gonad—testicular cancer	0.000107	0.00168	CbGeAlD
Sunitinib—NUAK2—testis—testicular cancer	0.000107	0.00168	CbGeAlD
Sunitinib—MAP3K12—testis—testicular cancer	0.000106	0.00167	CbGeAlD
Sunitinib—FLT3—testis—testicular cancer	0.000106	0.00167	CbGeAlD
Sunitinib—STK38—lymph node—testicular cancer	0.000106	0.00167	CbGeAlD
Sunitinib—RPS6KA2—lymph node—testicular cancer	0.000106	0.00167	CbGeAlD
Sunitinib—IRAK4—female gonad—testicular cancer	0.000106	0.00166	CbGeAlD
Sunitinib—AURKC—lymph node—testicular cancer	0.000106	0.00165	CbGeAlD
Sunitinib—PDGFRB—seminal vesicle—testicular cancer	0.000106	0.00165	CbGeAlD
Sunitinib—RPS6KA3—testis—testicular cancer	0.000105	0.00164	CbGeAlD
Sunitinib—PKN1—lymph node—testicular cancer	0.000105	0.00164	CbGeAlD
Sunitinib—CSNK1G2—lymph node—testicular cancer	0.000105	0.00164	CbGeAlD
Sunitinib—FLT1—gonad—testicular cancer	0.000104	0.00163	CbGeAlD
Sunitinib—MAP2K1—testis—testicular cancer	0.000104	0.00163	CbGeAlD
Sunitinib—ULK3—female gonad—testicular cancer	0.000103	0.00162	CbGeAlD
Sunitinib—MAP2K2—female gonad—testicular cancer	0.000103	0.00162	CbGeAlD
Sunitinib—PRPF4—lymph node—testicular cancer	0.000103	0.00162	CbGeAlD
Sunitinib—CSNK1A1—testis—testicular cancer	0.000103	0.00161	CbGeAlD
Sunitinib—MAP3K2—female gonad—testicular cancer	0.000103	0.00161	CbGeAlD
Sunitinib—CLK1—testis—testicular cancer	0.000102	0.0016	CbGeAlD
Sunitinib—MAP3K7—female gonad—testicular cancer	0.000102	0.00159	CbGeAlD
Sunitinib—PRPF4B—lymph node—testicular cancer	0.000102	0.00159	CbGeAlD
Sunitinib—TBK1—female gonad—testicular cancer	0.000101	0.00158	CbGeAlD
Sunitinib—STK39—lymph node—testicular cancer	0.0001	0.00157	CbGeAlD
Sunitinib—CAMK2G—testis—testicular cancer	0.0001	0.00157	CbGeAlD
Sunitinib—BMP2K—testis—testicular cancer	0.0001	0.00157	CbGeAlD
Sunitinib—TYK2—female gonad—testicular cancer	9.99e-05	0.00156	CbGeAlD
Sunitinib—YES1—gonad—testicular cancer	9.96e-05	0.00156	CbGeAlD
Sunitinib—LRRK2—testis—testicular cancer	9.94e-05	0.00156	CbGeAlD
Sunitinib—CSNK2A1—lymph node—testicular cancer	9.9e-05	0.00155	CbGeAlD
Sunitinib—STK10—gonad—testicular cancer	9.87e-05	0.00155	CbGeAlD
Sunitinib—IRAK1—female gonad—testicular cancer	9.86e-05	0.00154	CbGeAlD
Sunitinib—PRKAA1—testis—testicular cancer	9.8e-05	0.00153	CbGeAlD
Sunitinib—MYLK—lymph node—testicular cancer	9.77e-05	0.00153	CbGeAlD
Sunitinib—PDGFRA—gonad—testicular cancer	9.77e-05	0.00153	CbGeAlD
Sunitinib—PTK2B—testis—testicular cancer	9.69e-05	0.00152	CbGeAlD
Sunitinib—RPS6KB1—female gonad—testicular cancer	9.67e-05	0.00152	CbGeAlD
Sunitinib—FLT4—testis—testicular cancer	9.66e-05	0.00151	CbGeAlD
Sunitinib—PLK4—lymph node—testicular cancer	9.65e-05	0.00151	CbGeAlD
Sunitinib—FGR—female gonad—testicular cancer	9.62e-05	0.00151	CbGeAlD
Sunitinib—STK4—lymph node—testicular cancer	9.59e-05	0.0015	CbGeAlD
Sunitinib—AXL—female gonad—testicular cancer	9.58e-05	0.0015	CbGeAlD
Sunitinib—CSNK1E—testis—testicular cancer	9.53e-05	0.00149	CbGeAlD
Sunitinib—FGFR1—testis—testicular cancer	9.53e-05	0.00149	CbGeAlD
Sunitinib—PHKG2—lymph node—testicular cancer	9.42e-05	0.00148	CbGeAlD
Sunitinib—IRAK4—testis—testicular cancer	9.38e-05	0.00147	CbGeAlD
Sunitinib—STK24—lymph node—testicular cancer	9.37e-05	0.00147	CbGeAlD
Sunitinib—DAPK2—lymph node—testicular cancer	9.27e-05	0.00145	CbGeAlD
Sunitinib—SLK—female gonad—testicular cancer	9.22e-05	0.00144	CbGeAlD
Sunitinib—PLK4—Teniposide—Etoposide—testicular cancer	9.21e-05	0.0533	CbGdCrCtD
Sunitinib—ULK3—testis—testicular cancer	9.17e-05	0.00144	CbGeAlD
Sunitinib—MAP2K2—testis—testicular cancer	9.17e-05	0.00144	CbGeAlD
Sunitinib—FGFR2—female gonad—testicular cancer	9.14e-05	0.00143	CbGeAlD
Sunitinib—STK16—lymph node—testicular cancer	9.12e-05	0.00143	CbGeAlD
Sunitinib—MAP3K2—testis—testicular cancer	9.11e-05	0.00143	CbGeAlD
Sunitinib—JAK2—female gonad—testicular cancer	9.09e-05	0.00142	CbGeAlD
Sunitinib—HIPK3—lymph node—testicular cancer	9.07e-05	0.00142	CbGeAlD
Sunitinib—HIPK2—lymph node—testicular cancer	9.07e-05	0.00142	CbGeAlD
Sunitinib—ALK—lymph node—testicular cancer	9.07e-05	0.00142	CbGeAlD
Sunitinib—MAP3K7—testis—testicular cancer	9.02e-05	0.00141	CbGeAlD
Sunitinib—TNK1—lymph node—testicular cancer	8.97e-05	0.00141	CbGeAlD
Sunitinib—RIOK2—lymph node—testicular cancer	8.97e-05	0.00141	CbGeAlD
Sunitinib—FYN—female gonad—testicular cancer	8.96e-05	0.0014	CbGeAlD
Sunitinib—TBK1—testis—testicular cancer	8.92e-05	0.0014	CbGeAlD
Sunitinib—MAP4K1—lymph node—testicular cancer	8.88e-05	0.00139	CbGeAlD
Sunitinib—TYK2—testis—testicular cancer	8.86e-05	0.00139	CbGeAlD
Sunitinib—MAP4K5—female gonad—testicular cancer	8.76e-05	0.00137	CbGeAlD
Sunitinib—MAP3K3—female gonad—testicular cancer	8.76e-05	0.00137	CbGeAlD
Sunitinib—IRAK1—testis—testicular cancer	8.74e-05	0.00137	CbGeAlD
Sunitinib—DAPK3—lymph node—testicular cancer	8.71e-05	0.00136	CbGeAlD
Sunitinib—CLK2—lymph node—testicular cancer	8.63e-05	0.00135	CbGeAlD
Sunitinib—CSF1R—gonad—testicular cancer	8.6e-05	0.00135	CbGeAlD
Sunitinib—MAP4K2—lymph node—testicular cancer	8.59e-05	0.00135	CbGeAlD
Sunitinib—RPS6KB1—testis—testicular cancer	8.58e-05	0.00134	CbGeAlD
Sunitinib—FGR—testis—testicular cancer	8.53e-05	0.00134	CbGeAlD
Sunitinib—RET—testis—testicular cancer	8.53e-05	0.00134	CbGeAlD
Sunitinib—AXL—testis—testicular cancer	8.49e-05	0.00133	CbGeAlD
Sunitinib—STK3—lymph node—testicular cancer	8.47e-05	0.00133	CbGeAlD
Sunitinib—FLT1—female gonad—testicular cancer	8.47e-05	0.00133	CbGeAlD
Sunitinib—EPHB6—female gonad—testicular cancer	8.37e-05	0.00131	CbGeAlD
Sunitinib—SLK—testis—testicular cancer	8.18e-05	0.00128	CbGeAlD
Sunitinib—DYRK1A—lymph node—testicular cancer	8.16e-05	0.00128	CbGeAlD
Sunitinib—CHEK2—Vinorelbine—Vinblastine—testicular cancer	8.12e-05	0.047	CbGdCrCtD
Sunitinib—CHEK2—Teniposide—Etoposide—testicular cancer	8.12e-05	0.0469	CbGdCrCtD
Sunitinib—CHEK2—Podofilox—Etoposide—testicular cancer	8.12e-05	0.0469	CbGdCrCtD
Sunitinib—FGFR2—testis—testicular cancer	8.1e-05	0.00127	CbGeAlD
Sunitinib—YES1—female gonad—testicular cancer	8.09e-05	0.00127	CbGeAlD
Sunitinib—JAK2—testis—testicular cancer	8.06e-05	0.00126	CbGeAlD
Sunitinib—STK10—female gonad—testicular cancer	8.02e-05	0.00126	CbGeAlD
Sunitinib—TAOK3—female gonad—testicular cancer	7.99e-05	0.00125	CbGeAlD
Sunitinib—MERTK—lymph node—testicular cancer	7.97e-05	0.00125	CbGeAlD
Sunitinib—FYN—testis—testicular cancer	7.95e-05	0.00125	CbGeAlD
Sunitinib—PDGFRA—female gonad—testicular cancer	7.94e-05	0.00124	CbGeAlD
Sunitinib—MAP4K4—lymph node—testicular cancer	7.82e-05	0.00123	CbGeAlD
Sunitinib—KIT—gonad—testicular cancer	7.81e-05	0.00122	CbGeAlD
Sunitinib—MAP3K3—testis—testicular cancer	7.77e-05	0.00122	CbGeAlD
Sunitinib—MAP4K5—testis—testicular cancer	7.77e-05	0.00122	CbGeAlD
Sunitinib—NUAK2—lymph node—testicular cancer	7.76e-05	0.00122	CbGeAlD
Sunitinib—FLT3—lymph node—testicular cancer	7.71e-05	0.00121	CbGeAlD
Sunitinib—MAP3K12—lymph node—testicular cancer	7.71e-05	0.00121	CbGeAlD
Sunitinib—PDGFRB—gonad—testicular cancer	7.63e-05	0.00119	CbGeAlD
Sunitinib—RPS6KA3—lymph node—testicular cancer	7.6e-05	0.00119	CbGeAlD
Sunitinib—MAP2K1—lymph node—testicular cancer	7.55e-05	0.00118	CbGeAlD
Sunitinib—FLT1—testis—testicular cancer	7.51e-05	0.00118	CbGeAlD
Sunitinib—CSNK1A1—lymph node—testicular cancer	7.45e-05	0.00117	CbGeAlD
Sunitinib—EPHB6—testis—testicular cancer	7.42e-05	0.00116	CbGeAlD
Sunitinib—CLK1—lymph node—testicular cancer	7.41e-05	0.00116	CbGeAlD
Sunitinib—BMP2K—lymph node—testicular cancer	7.27e-05	0.00114	CbGeAlD
Sunitinib—CAMK2G—lymph node—testicular cancer	7.27e-05	0.00114	CbGeAlD
Sunitinib—LRRK2—lymph node—testicular cancer	7.21e-05	0.00113	CbGeAlD
Sunitinib—YES1—testis—testicular cancer	7.18e-05	0.00112	CbGeAlD
Sunitinib—KDR—female gonad—testicular cancer	7.16e-05	0.00112	CbGeAlD
Sunitinib—MAP2K5—female gonad—testicular cancer	7.16e-05	0.00112	CbGeAlD
Sunitinib—STK10—testis—testicular cancer	7.11e-05	0.00111	CbGeAlD
Sunitinib—PRKAA1—lymph node—testicular cancer	7.1e-05	0.00111	CbGeAlD
Sunitinib—TAOK3—testis—testicular cancer	7.08e-05	0.00111	CbGeAlD
Sunitinib—PDGFRA—testis—testicular cancer	7.04e-05	0.0011	CbGeAlD
Sunitinib—DYRK1A—Doxorubicin—Epirubicin—testicular cancer	7.03e-05	0.0407	CbGdCrCtD
Sunitinib—DYRK1A—Idarubicin—Epirubicin—testicular cancer	7.03e-05	0.0407	CbGdCrCtD
Sunitinib—DYRK1A—Daunorubicin—Epirubicin—testicular cancer	7.03e-05	0.0407	CbGdCrCtD
Sunitinib—PTK2B—lymph node—testicular cancer	7.02e-05	0.0011	CbGeAlD
Sunitinib—FLT4—lymph node—testicular cancer	7e-05	0.0011	CbGeAlD
Sunitinib—CSF1R—female gonad—testicular cancer	6.99e-05	0.00109	CbGeAlD
Sunitinib—CHEK2—Vincristine—Vinblastine—testicular cancer	6.94e-05	0.0402	CbGdCrCtD
Sunitinib—CSNK1E—lymph node—testicular cancer	6.91e-05	0.00108	CbGeAlD
Sunitinib—FGFR1—lymph node—testicular cancer	6.91e-05	0.00108	CbGeAlD
Sunitinib—IRAK4—lymph node—testicular cancer	6.8e-05	0.00107	CbGeAlD
Sunitinib—KCNH2—seminal vesicle—testicular cancer	6.67e-05	0.00104	CbGeAlD
Sunitinib—ULK3—lymph node—testicular cancer	6.65e-05	0.00104	CbGeAlD
Sunitinib—MAP2K2—lymph node—testicular cancer	6.65e-05	0.00104	CbGeAlD
Sunitinib—MAP3K2—lymph node—testicular cancer	6.6e-05	0.00103	CbGeAlD
Sunitinib—MAP3K7—lymph node—testicular cancer	6.54e-05	0.00102	CbGeAlD
Sunitinib—DYRK1A—Epirubicin—Doxorubicin—testicular cancer	6.5e-05	0.0376	CbGdCrCtD
Sunitinib—DYRK1A—Idarubicin—Doxorubicin—testicular cancer	6.5e-05	0.0376	CbGdCrCtD
Sunitinib—DYRK1A—Daunorubicin—Doxorubicin—testicular cancer	6.5e-05	0.0376	CbGdCrCtD
Sunitinib—TBK1—lymph node—testicular cancer	6.47e-05	0.00101	CbGeAlD
Sunitinib—TYK2—lymph node—testicular cancer	6.42e-05	0.00101	CbGeAlD
Sunitinib—KDR—testis—testicular cancer	6.35e-05	0.000995	CbGeAlD
Sunitinib—MAP2K5—testis—testicular cancer	6.35e-05	0.000995	CbGeAlD
Sunitinib—KIT—female gonad—testicular cancer	6.34e-05	0.000994	CbGeAlD
Sunitinib—IRAK1—lymph node—testicular cancer	6.34e-05	0.000993	CbGeAlD
Sunitinib—RPS6KB1—lymph node—testicular cancer	6.22e-05	0.000974	CbGeAlD
Sunitinib—CSF1R—testis—testicular cancer	6.2e-05	0.000971	CbGeAlD
Sunitinib—PDGFRB—female gonad—testicular cancer	6.2e-05	0.000971	CbGeAlD
Sunitinib—FGR—lymph node—testicular cancer	6.18e-05	0.000968	CbGeAlD
Sunitinib—RET—lymph node—testicular cancer	6.18e-05	0.000968	CbGeAlD
Sunitinib—AXL—lymph node—testicular cancer	6.16e-05	0.000965	CbGeAlD
Sunitinib—PRPF4—Idarubicin—Epirubicin—testicular cancer	6.07e-05	0.0351	CbGdCrCtD
Sunitinib—PRPF4—Daunorubicin—Epirubicin—testicular cancer	6.07e-05	0.0351	CbGdCrCtD
Sunitinib—ABCG2—seminal vesicle—testicular cancer	5.93e-05	0.000929	CbGeAlD
Sunitinib—SLK—lymph node—testicular cancer	5.93e-05	0.000928	CbGeAlD
Sunitinib—JAK2—lymph node—testicular cancer	5.84e-05	0.000915	CbGeAlD
Sunitinib—FYN—lymph node—testicular cancer	5.76e-05	0.000903	CbGeAlD
Sunitinib—MAP3K3—lymph node—testicular cancer	5.63e-05	0.000882	CbGeAlD
Sunitinib—MAP4K5—lymph node—testicular cancer	5.63e-05	0.000882	CbGeAlD
Sunitinib—KIT—testis—testicular cancer	5.63e-05	0.000881	CbGeAlD
Sunitinib—PRPF4—Idarubicin—Doxorubicin—testicular cancer	5.61e-05	0.0325	CbGdCrCtD
Sunitinib—PRPF4—Daunorubicin—Doxorubicin—testicular cancer	5.61e-05	0.0325	CbGdCrCtD
Sunitinib—PDGFRB—testis—testicular cancer	5.5e-05	0.000861	CbGeAlD
Sunitinib—FLT1—lymph node—testicular cancer	5.44e-05	0.000853	CbGeAlD
Sunitinib—EPHB6—lymph node—testicular cancer	5.38e-05	0.000843	CbGeAlD
Sunitinib—YES1—lymph node—testicular cancer	5.2e-05	0.000815	CbGeAlD
Sunitinib—STK10—lymph node—testicular cancer	5.15e-05	0.000807	CbGeAlD
Sunitinib—TAOK3—lymph node—testicular cancer	5.13e-05	0.000804	CbGeAlD
Sunitinib—PDGFRA—lymph node—testicular cancer	5.1e-05	0.000799	CbGeAlD
Sunitinib—ABCC4—female gonad—testicular cancer	4.93e-05	0.000773	CbGeAlD
Sunitinib—PLK4—Doxorubicin—Epirubicin—testicular cancer	4.8e-05	0.0278	CbGdCrCtD
Sunitinib—PLK4—Idarubicin—Epirubicin—testicular cancer	4.8e-05	0.0278	CbGdCrCtD
Sunitinib—MAP2K5—lymph node—testicular cancer	4.6e-05	0.000721	CbGeAlD
Sunitinib—KDR—lymph node—testicular cancer	4.6e-05	0.000721	CbGeAlD
Sunitinib—CSF1R—lymph node—testicular cancer	4.49e-05	0.000704	CbGeAlD
Sunitinib—PLK4—Epirubicin—Doxorubicin—testicular cancer	4.44e-05	0.0257	CbGdCrCtD
Sunitinib—PLK4—Idarubicin—Doxorubicin—testicular cancer	4.44e-05	0.0257	CbGdCrCtD
Sunitinib—ABCC4—testis—testicular cancer	4.38e-05	0.000686	CbGeAlD
Sunitinib—ABCC2—testis—testicular cancer	4.24e-05	0.000664	CbGeAlD
Sunitinib—CHEK2—Doxorubicin—Epirubicin—testicular cancer	4.23e-05	0.0245	CbGdCrCtD
Sunitinib—KIT—lymph node—testicular cancer	4.08e-05	0.000639	CbGeAlD
Sunitinib—PDGFRB—lymph node—testicular cancer	3.98e-05	0.000624	CbGeAlD
Sunitinib—CHEK2—Epirubicin—Doxorubicin—testicular cancer	3.92e-05	0.0226	CbGdCrCtD
Sunitinib—KCNH2—female gonad—testicular cancer	3.92e-05	0.000613	CbGeAlD
Sunitinib—ABCG2—female gonad—testicular cancer	3.48e-05	0.000546	CbGeAlD
Sunitinib—KCNH2—testis—testicular cancer	3.47e-05	0.000544	CbGeAlD
Sunitinib—CYP3A5—female gonad—testicular cancer	3.23e-05	0.000506	CbGeAlD
Sunitinib—ABCC4—lymph node—testicular cancer	3.17e-05	0.000497	CbGeAlD
Sunitinib—ABCB1—embryo—testicular cancer	3.11e-05	0.000488	CbGeAlD
Sunitinib—ABCG2—testis—testicular cancer	3.09e-05	0.000484	CbGeAlD
Sunitinib—ABCC2—lymph node—testicular cancer	3.07e-05	0.000481	CbGeAlD
Sunitinib—Hyperglycaemia—Epirubicin—testicular cancer	3.01e-05	0.000431	CcSEcCtD
Sunitinib—Hepatobiliary disease—Methotrexate—testicular cancer	3e-05	0.00043	CcSEcCtD
Sunitinib—Epistaxis—Methotrexate—testicular cancer	2.99e-05	0.000429	CcSEcCtD
Sunitinib—Pneumonia—Epirubicin—testicular cancer	2.99e-05	0.000428	CcSEcCtD
Sunitinib—Nausea—Bleomycin—testicular cancer	2.98e-05	0.000426	CcSEcCtD
Sunitinib—Infestation—Epirubicin—testicular cancer	2.97e-05	0.000426	CcSEcCtD
Sunitinib—Infestation NOS—Epirubicin—testicular cancer	2.97e-05	0.000426	CcSEcCtD
Sunitinib—Vomiting—Dactinomycin—testicular cancer	2.97e-05	0.000426	CcSEcCtD
Sunitinib—Bronchitis—Doxorubicin—testicular cancer	2.97e-05	0.000425	CcSEcCtD
Sunitinib—Stevens-Johnson syndrome—Epirubicin—testicular cancer	2.95e-05	0.000422	CcSEcCtD
Sunitinib—Rash—Dactinomycin—testicular cancer	2.95e-05	0.000422	CcSEcCtD
Sunitinib—Decreased appetite—Etoposide—testicular cancer	2.94e-05	0.000421	CcSEcCtD
Sunitinib—Diarrhoea—Ifosfamide—testicular cancer	2.93e-05	0.00042	CcSEcCtD
Sunitinib—Pancytopenia—Doxorubicin—testicular cancer	2.93e-05	0.00042	CcSEcCtD
Sunitinib—ABCB1—seminal vesicle—testicular cancer	2.92e-05	0.000458	CbGeAlD
Sunitinib—Renal failure—Epirubicin—testicular cancer	2.92e-05	0.000419	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Etoposide—testicular cancer	2.92e-05	0.000418	CcSEcCtD
Sunitinib—Body temperature increased—Cisplatin—testicular cancer	2.92e-05	0.000418	CcSEcCtD
Sunitinib—Fatigue—Etoposide—testicular cancer	2.91e-05	0.000418	CcSEcCtD
Sunitinib—Neuropathy peripheral—Epirubicin—testicular cancer	2.91e-05	0.000417	CcSEcCtD
Sunitinib—Stomatitis—Epirubicin—testicular cancer	2.9e-05	0.000415	CcSEcCtD
Sunitinib—Pain—Etoposide—testicular cancer	2.89e-05	0.000414	CcSEcCtD
Sunitinib—Constipation—Etoposide—testicular cancer	2.89e-05	0.000414	CcSEcCtD
Sunitinib—Urinary tract infection—Epirubicin—testicular cancer	2.89e-05	0.000414	CcSEcCtD
Sunitinib—Neutropenia—Doxorubicin—testicular cancer	2.88e-05	0.000413	CcSEcCtD
Sunitinib—Upper respiratory tract infection—Doxorubicin—testicular cancer	2.87e-05	0.000411	CcSEcCtD
Sunitinib—Haemoglobin—Methotrexate—testicular cancer	2.86e-05	0.000411	CcSEcCtD
Sunitinib—Hepatitis—Methotrexate—testicular cancer	2.85e-05	0.000409	CcSEcCtD
Sunitinib—Haemorrhage—Methotrexate—testicular cancer	2.85e-05	0.000409	CcSEcCtD
Sunitinib—Dizziness—Ifosfamide—testicular cancer	2.83e-05	0.000406	CcSEcCtD
Sunitinib—Urinary tract disorder—Methotrexate—testicular cancer	2.81e-05	0.000403	CcSEcCtD
Sunitinib—Hepatobiliary disease—Epirubicin—testicular cancer	2.81e-05	0.000403	CcSEcCtD
Sunitinib—Epistaxis—Epirubicin—testicular cancer	2.8e-05	0.000402	CcSEcCtD
Sunitinib—Urethral disorder—Methotrexate—testicular cancer	2.79e-05	0.0004	CcSEcCtD
Sunitinib—Weight decreased—Doxorubicin—testicular cancer	2.79e-05	0.0004	CcSEcCtD
Sunitinib—Hyperglycaemia—Doxorubicin—testicular cancer	2.78e-05	0.000399	CcSEcCtD
Sunitinib—Nausea—Dactinomycin—testicular cancer	2.77e-05	0.000398	CcSEcCtD
Sunitinib—Pneumonia—Doxorubicin—testicular cancer	2.77e-05	0.000396	CcSEcCtD
Sunitinib—Gastrointestinal pain—Etoposide—testicular cancer	2.76e-05	0.000396	CcSEcCtD
Sunitinib—Infestation NOS—Doxorubicin—testicular cancer	2.75e-05	0.000394	CcSEcCtD
Sunitinib—Infestation—Doxorubicin—testicular cancer	2.75e-05	0.000394	CcSEcCtD
Sunitinib—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	2.73e-05	0.000391	CcSEcCtD
Sunitinib—Vomiting—Ifosfamide—testicular cancer	2.72e-05	0.00039	CcSEcCtD
Sunitinib—Hypersensitivity—Cisplatin—testicular cancer	2.72e-05	0.00039	CcSEcCtD
Sunitinib—Bradycardia—Epirubicin—testicular cancer	2.72e-05	0.000389	CcSEcCtD
Sunitinib—Renal failure—Doxorubicin—testicular cancer	2.7e-05	0.000387	CcSEcCtD
Sunitinib—Rash—Ifosfamide—testicular cancer	2.7e-05	0.000387	CcSEcCtD
Sunitinib—Dermatitis—Ifosfamide—testicular cancer	2.7e-05	0.000386	CcSEcCtD
Sunitinib—Erythema multiforme—Methotrexate—testicular cancer	2.7e-05	0.000386	CcSEcCtD
Sunitinib—Neuropathy peripheral—Doxorubicin—testicular cancer	2.7e-05	0.000386	CcSEcCtD
Sunitinib—Haemoglobin—Epirubicin—testicular cancer	2.68e-05	0.000384	CcSEcCtD
Sunitinib—Stomatitis—Doxorubicin—testicular cancer	2.68e-05	0.000384	CcSEcCtD
Sunitinib—Abdominal pain—Etoposide—testicular cancer	2.67e-05	0.000383	CcSEcCtD
Sunitinib—Body temperature increased—Etoposide—testicular cancer	2.67e-05	0.000383	CcSEcCtD
Sunitinib—Urinary tract infection—Doxorubicin—testicular cancer	2.67e-05	0.000383	CcSEcCtD
Sunitinib—Hepatitis—Epirubicin—testicular cancer	2.67e-05	0.000382	CcSEcCtD
Sunitinib—Haemorrhage—Epirubicin—testicular cancer	2.67e-05	0.000382	CcSEcCtD
Sunitinib—Eye disorder—Methotrexate—testicular cancer	2.66e-05	0.000382	CcSEcCtD
Sunitinib—Hypoaesthesia—Epirubicin—testicular cancer	2.65e-05	0.00038	CcSEcCtD
Sunitinib—Asthenia—Cisplatin—testicular cancer	2.65e-05	0.000379	CcSEcCtD
Sunitinib—Cardiac disorder—Methotrexate—testicular cancer	2.65e-05	0.000379	CcSEcCtD
Sunitinib—Urinary tract disorder—Epirubicin—testicular cancer	2.63e-05	0.000378	CcSEcCtD
Sunitinib—Oedema peripheral—Epirubicin—testicular cancer	2.63e-05	0.000377	CcSEcCtD
Sunitinib—Connective tissue disorder—Epirubicin—testicular cancer	2.62e-05	0.000376	CcSEcCtD
Sunitinib—Urethral disorder—Epirubicin—testicular cancer	2.61e-05	0.000375	CcSEcCtD
Sunitinib—Hepatobiliary disease—Doxorubicin—testicular cancer	2.6e-05	0.000373	CcSEcCtD
Sunitinib—Epistaxis—Doxorubicin—testicular cancer	2.59e-05	0.000372	CcSEcCtD
Sunitinib—Angiopathy—Methotrexate—testicular cancer	2.59e-05	0.000371	CcSEcCtD
Sunitinib—Immune system disorder—Methotrexate—testicular cancer	2.57e-05	0.000369	CcSEcCtD
Sunitinib—Mediastinal disorder—Methotrexate—testicular cancer	2.57e-05	0.000368	CcSEcCtD
Sunitinib—Chills—Methotrexate—testicular cancer	2.56e-05	0.000367	CcSEcCtD
Sunitinib—Nausea—Ifosfamide—testicular cancer	2.54e-05	0.000364	CcSEcCtD
Sunitinib—Diarrhoea—Cisplatin—testicular cancer	2.53e-05	0.000362	CcSEcCtD
Sunitinib—Erythema multiforme—Epirubicin—testicular cancer	2.52e-05	0.000361	CcSEcCtD
Sunitinib—Alopecia—Methotrexate—testicular cancer	2.52e-05	0.000361	CcSEcCtD
Sunitinib—KCNH2—lymph node—testicular cancer	2.52e-05	0.000394	CbGeAlD
Sunitinib—Bradycardia—Doxorubicin—testicular cancer	2.51e-05	0.00036	CcSEcCtD
Sunitinib—Mental disorder—Methotrexate—testicular cancer	2.5e-05	0.000358	CcSEcCtD
Sunitinib—Eye disorder—Epirubicin—testicular cancer	2.49e-05	0.000357	CcSEcCtD
Sunitinib—Hypersensitivity—Etoposide—testicular cancer	2.49e-05	0.000357	CcSEcCtD
Sunitinib—Erythema—Methotrexate—testicular cancer	2.48e-05	0.000356	CcSEcCtD
Sunitinib—Malnutrition—Methotrexate—testicular cancer	2.48e-05	0.000356	CcSEcCtD
Sunitinib—Haemoglobin—Doxorubicin—testicular cancer	2.48e-05	0.000356	CcSEcCtD
Sunitinib—Flushing—Epirubicin—testicular cancer	2.48e-05	0.000355	CcSEcCtD
Sunitinib—Cardiac disorder—Epirubicin—testicular cancer	2.48e-05	0.000355	CcSEcCtD
Sunitinib—Hepatitis—Doxorubicin—testicular cancer	2.47e-05	0.000354	CcSEcCtD
Sunitinib—Haemorrhage—Doxorubicin—testicular cancer	2.47e-05	0.000354	CcSEcCtD
Sunitinib—Hypoaesthesia—Doxorubicin—testicular cancer	2.46e-05	0.000352	CcSEcCtD
Sunitinib—Urinary tract disorder—Doxorubicin—testicular cancer	2.44e-05	0.000349	CcSEcCtD
Sunitinib—Oedema peripheral—Doxorubicin—testicular cancer	2.43e-05	0.000348	CcSEcCtD
Sunitinib—Dysgeusia—Methotrexate—testicular cancer	2.43e-05	0.000348	CcSEcCtD
Sunitinib—Asthenia—Etoposide—testicular cancer	2.43e-05	0.000348	CcSEcCtD
Sunitinib—Connective tissue disorder—Doxorubicin—testicular cancer	2.43e-05	0.000348	CcSEcCtD
Sunitinib—Angiopathy—Epirubicin—testicular cancer	2.42e-05	0.000347	CcSEcCtD
Sunitinib—Urethral disorder—Doxorubicin—testicular cancer	2.42e-05	0.000347	CcSEcCtD
Sunitinib—Immune system disorder—Epirubicin—testicular cancer	2.41e-05	0.000345	CcSEcCtD
Sunitinib—Mediastinal disorder—Epirubicin—testicular cancer	2.4e-05	0.000345	CcSEcCtD
Sunitinib—Back pain—Methotrexate—testicular cancer	2.4e-05	0.000344	CcSEcCtD
Sunitinib—Chills—Epirubicin—testicular cancer	2.39e-05	0.000343	CcSEcCtD
Sunitinib—Pruritus—Etoposide—testicular cancer	2.39e-05	0.000343	CcSEcCtD
Sunitinib—Arrhythmia—Epirubicin—testicular cancer	2.38e-05	0.000342	CcSEcCtD
Sunitinib—Alopecia—Epirubicin—testicular cancer	2.36e-05	0.000338	CcSEcCtD
Sunitinib—Vomiting—Cisplatin—testicular cancer	2.35e-05	0.000336	CcSEcCtD
Sunitinib—Mental disorder—Epirubicin—testicular cancer	2.34e-05	0.000335	CcSEcCtD
Sunitinib—Erythema multiforme—Doxorubicin—testicular cancer	2.33e-05	0.000334	CcSEcCtD
Sunitinib—Rash—Cisplatin—testicular cancer	2.33e-05	0.000333	CcSEcCtD
Sunitinib—Dermatitis—Cisplatin—testicular cancer	2.32e-05	0.000333	CcSEcCtD
Sunitinib—Malnutrition—Epirubicin—testicular cancer	2.32e-05	0.000333	CcSEcCtD
Sunitinib—Erythema—Epirubicin—testicular cancer	2.32e-05	0.000333	CcSEcCtD
Sunitinib—Diarrhoea—Etoposide—testicular cancer	2.31e-05	0.000332	CcSEcCtD
Sunitinib—Eye disorder—Doxorubicin—testicular cancer	2.31e-05	0.000331	CcSEcCtD
Sunitinib—Anaemia—Methotrexate—testicular cancer	2.29e-05	0.000329	CcSEcCtD
Sunitinib—Flushing—Doxorubicin—testicular cancer	2.29e-05	0.000328	CcSEcCtD
Sunitinib—Cardiac disorder—Doxorubicin—testicular cancer	2.29e-05	0.000328	CcSEcCtD
Sunitinib—Flatulence—Epirubicin—testicular cancer	2.29e-05	0.000328	CcSEcCtD
Sunitinib—Dysgeusia—Epirubicin—testicular cancer	2.27e-05	0.000326	CcSEcCtD
Sunitinib—Back pain—Epirubicin—testicular cancer	2.25e-05	0.000322	CcSEcCtD
Sunitinib—Angiopathy—Doxorubicin—testicular cancer	2.24e-05	0.000321	CcSEcCtD
Sunitinib—ABCG2—lymph node—testicular cancer	2.24e-05	0.000351	CbGeAlD
Sunitinib—Dizziness—Etoposide—testicular cancer	2.24e-05	0.00032	CcSEcCtD
Sunitinib—Muscle spasms—Epirubicin—testicular cancer	2.23e-05	0.00032	CcSEcCtD
Sunitinib—Immune system disorder—Doxorubicin—testicular cancer	2.23e-05	0.00032	CcSEcCtD
Sunitinib—Mediastinal disorder—Doxorubicin—testicular cancer	2.22e-05	0.000319	CcSEcCtD
Sunitinib—Leukopenia—Methotrexate—testicular cancer	2.22e-05	0.000318	CcSEcCtD
Sunitinib—Chills—Doxorubicin—testicular cancer	2.21e-05	0.000317	CcSEcCtD
Sunitinib—Arrhythmia—Doxorubicin—testicular cancer	2.2e-05	0.000316	CcSEcCtD
Sunitinib—Nausea—Cisplatin—testicular cancer	2.19e-05	0.000314	CcSEcCtD
Sunitinib—Alopecia—Doxorubicin—testicular cancer	2.18e-05	0.000313	CcSEcCtD
Sunitinib—Cough—Methotrexate—testicular cancer	2.17e-05	0.00031	CcSEcCtD
Sunitinib—Mental disorder—Doxorubicin—testicular cancer	2.16e-05	0.00031	CcSEcCtD
Sunitinib—Convulsion—Methotrexate—testicular cancer	2.15e-05	0.000308	CcSEcCtD
Sunitinib—Vomiting—Etoposide—testicular cancer	2.15e-05	0.000308	CcSEcCtD
Sunitinib—Malnutrition—Doxorubicin—testicular cancer	2.15e-05	0.000308	CcSEcCtD
Sunitinib—Erythema—Doxorubicin—testicular cancer	2.15e-05	0.000308	CcSEcCtD
Sunitinib—Anaemia—Epirubicin—testicular cancer	2.15e-05	0.000308	CcSEcCtD
Sunitinib—Rash—Etoposide—testicular cancer	2.13e-05	0.000306	CcSEcCtD
Sunitinib—Dermatitis—Etoposide—testicular cancer	2.13e-05	0.000305	CcSEcCtD
Sunitinib—Headache—Etoposide—testicular cancer	2.12e-05	0.000304	CcSEcCtD
Sunitinib—Flatulence—Doxorubicin—testicular cancer	2.12e-05	0.000303	CcSEcCtD
Sunitinib—ABCB1—gonad—testicular cancer	2.11e-05	0.000331	CbGeAlD
Sunitinib—Chest pain—Methotrexate—testicular cancer	2.11e-05	0.000303	CcSEcCtD
Sunitinib—Arthralgia—Methotrexate—testicular cancer	2.11e-05	0.000303	CcSEcCtD
Sunitinib—Myalgia—Methotrexate—testicular cancer	2.11e-05	0.000303	CcSEcCtD
Sunitinib—Dysgeusia—Doxorubicin—testicular cancer	2.1e-05	0.000302	CcSEcCtD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	2.1e-05	0.000301	CcSEcCtD
Sunitinib—Leukopenia—Epirubicin—testicular cancer	2.08e-05	0.000298	CcSEcCtD
Sunitinib—Back pain—Doxorubicin—testicular cancer	2.08e-05	0.000298	CcSEcCtD
Sunitinib—Muscle spasms—Doxorubicin—testicular cancer	2.07e-05	0.000296	CcSEcCtD
Sunitinib—Cough—Epirubicin—testicular cancer	2.03e-05	0.00029	CcSEcCtD
Sunitinib—Convulsion—Epirubicin—testicular cancer	2.01e-05	0.000288	CcSEcCtD
Sunitinib—Infection—Methotrexate—testicular cancer	2.01e-05	0.000288	CcSEcCtD
Sunitinib—Nausea—Etoposide—testicular cancer	2.01e-05	0.000288	CcSEcCtD
Sunitinib—Hypertension—Epirubicin—testicular cancer	2e-05	0.000287	CcSEcCtD
Sunitinib—Nervous system disorder—Methotrexate—testicular cancer	1.99e-05	0.000285	CcSEcCtD
Sunitinib—Anaemia—Doxorubicin—testicular cancer	1.99e-05	0.000285	CcSEcCtD
Sunitinib—Thrombocytopenia—Methotrexate—testicular cancer	1.98e-05	0.000284	CcSEcCtD
Sunitinib—Arthralgia—Epirubicin—testicular cancer	1.98e-05	0.000283	CcSEcCtD
Sunitinib—Chest pain—Epirubicin—testicular cancer	1.98e-05	0.000283	CcSEcCtD
Sunitinib—Myalgia—Epirubicin—testicular cancer	1.98e-05	0.000283	CcSEcCtD
Sunitinib—Skin disorder—Methotrexate—testicular cancer	1.97e-05	0.000282	CcSEcCtD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	1.96e-05	0.000281	CcSEcCtD
Sunitinib—Dry mouth—Epirubicin—testicular cancer	1.93e-05	0.000277	CcSEcCtD
Sunitinib—Anorexia—Methotrexate—testicular cancer	1.93e-05	0.000277	CcSEcCtD
Sunitinib—Leukopenia—Doxorubicin—testicular cancer	1.92e-05	0.000276	CcSEcCtD
Sunitinib—Oedema—Epirubicin—testicular cancer	1.9e-05	0.000272	CcSEcCtD
Sunitinib—Infection—Epirubicin—testicular cancer	1.88e-05	0.00027	CcSEcCtD
Sunitinib—Cough—Doxorubicin—testicular cancer	1.87e-05	0.000269	CcSEcCtD
Sunitinib—Shock—Epirubicin—testicular cancer	1.86e-05	0.000267	CcSEcCtD
Sunitinib—Convulsion—Doxorubicin—testicular cancer	1.86e-05	0.000267	CcSEcCtD
Sunitinib—Nervous system disorder—Epirubicin—testicular cancer	1.86e-05	0.000266	CcSEcCtD
Sunitinib—Thrombocytopenia—Epirubicin—testicular cancer	1.86e-05	0.000266	CcSEcCtD
Sunitinib—Hypertension—Doxorubicin—testicular cancer	1.86e-05	0.000266	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Methotrexate—testicular cancer	1.85e-05	0.000264	CcSEcCtD
Sunitinib—Skin disorder—Epirubicin—testicular cancer	1.84e-05	0.000264	CcSEcCtD
Sunitinib—Insomnia—Methotrexate—testicular cancer	1.83e-05	0.000263	CcSEcCtD
Sunitinib—Chest pain—Doxorubicin—testicular cancer	1.83e-05	0.000262	CcSEcCtD
Sunitinib—Arthralgia—Doxorubicin—testicular cancer	1.83e-05	0.000262	CcSEcCtD
Sunitinib—Myalgia—Doxorubicin—testicular cancer	1.83e-05	0.000262	CcSEcCtD
Sunitinib—Paraesthesia—Methotrexate—testicular cancer	1.82e-05	0.000261	CcSEcCtD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	1.82e-05	0.00026	CcSEcCtD
Sunitinib—Anorexia—Epirubicin—testicular cancer	1.81e-05	0.000259	CcSEcCtD
Sunitinib—Dyspnoea—Methotrexate—testicular cancer	1.81e-05	0.000259	CcSEcCtD
Sunitinib—Dry mouth—Doxorubicin—testicular cancer	1.79e-05	0.000256	CcSEcCtD
Sunitinib—Dyspepsia—Methotrexate—testicular cancer	1.78e-05	0.000255	CcSEcCtD
Sunitinib—Decreased appetite—Methotrexate—testicular cancer	1.76e-05	0.000252	CcSEcCtD
Sunitinib—Oedema—Doxorubicin—testicular cancer	1.75e-05	0.000251	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Methotrexate—testicular cancer	1.75e-05	0.000251	CcSEcCtD
Sunitinib—Fatigue—Methotrexate—testicular cancer	1.75e-05	0.00025	CcSEcCtD
Sunitinib—Infection—Doxorubicin—testicular cancer	1.74e-05	0.00025	CcSEcCtD
Sunitinib—Pain—Methotrexate—testicular cancer	1.73e-05	0.000248	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Epirubicin—testicular cancer	1.73e-05	0.000247	CcSEcCtD
Sunitinib—Shock—Doxorubicin—testicular cancer	1.73e-05	0.000247	CcSEcCtD
Sunitinib—Nervous system disorder—Doxorubicin—testicular cancer	1.72e-05	0.000246	CcSEcCtD
Sunitinib—ABCB1—female gonad—testicular cancer	1.72e-05	0.000269	CbGeAlD
Sunitinib—Thrombocytopenia—Doxorubicin—testicular cancer	1.72e-05	0.000246	CcSEcCtD
Sunitinib—Insomnia—Epirubicin—testicular cancer	1.71e-05	0.000246	CcSEcCtD
Sunitinib—Skin disorder—Doxorubicin—testicular cancer	1.7e-05	0.000244	CcSEcCtD
Sunitinib—Paraesthesia—Epirubicin—testicular cancer	1.7e-05	0.000244	CcSEcCtD
Sunitinib—Dyspnoea—Epirubicin—testicular cancer	1.69e-05	0.000242	CcSEcCtD
Sunitinib—Anorexia—Doxorubicin—testicular cancer	1.67e-05	0.00024	CcSEcCtD
Sunitinib—Dyspepsia—Epirubicin—testicular cancer	1.67e-05	0.000239	CcSEcCtD
Sunitinib—Gastrointestinal pain—Methotrexate—testicular cancer	1.66e-05	0.000237	CcSEcCtD
Sunitinib—Decreased appetite—Epirubicin—testicular cancer	1.65e-05	0.000236	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Epirubicin—testicular cancer	1.64e-05	0.000234	CcSEcCtD
Sunitinib—Fatigue—Epirubicin—testicular cancer	1.63e-05	0.000234	CcSEcCtD
Sunitinib—Constipation—Epirubicin—testicular cancer	1.62e-05	0.000232	CcSEcCtD
Sunitinib—Pain—Epirubicin—testicular cancer	1.62e-05	0.000232	CcSEcCtD
Sunitinib—Abdominal pain—Methotrexate—testicular cancer	1.6e-05	0.000229	CcSEcCtD
Sunitinib—Body temperature increased—Methotrexate—testicular cancer	1.6e-05	0.000229	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Doxorubicin—testicular cancer	1.6e-05	0.000229	CcSEcCtD
Sunitinib—Insomnia—Doxorubicin—testicular cancer	1.59e-05	0.000227	CcSEcCtD
Sunitinib—Paraesthesia—Doxorubicin—testicular cancer	1.57e-05	0.000226	CcSEcCtD
Sunitinib—Dyspnoea—Doxorubicin—testicular cancer	1.56e-05	0.000224	CcSEcCtD
Sunitinib—Gastrointestinal pain—Epirubicin—testicular cancer	1.55e-05	0.000222	CcSEcCtD
Sunitinib—Dyspepsia—Doxorubicin—testicular cancer	1.54e-05	0.000221	CcSEcCtD
Sunitinib—Decreased appetite—Doxorubicin—testicular cancer	1.52e-05	0.000218	CcSEcCtD
Sunitinib—ABCB1—testis—testicular cancer	1.52e-05	0.000239	CbGeAlD
Sunitinib—Gastrointestinal disorder—Doxorubicin—testicular cancer	1.51e-05	0.000217	CcSEcCtD
Sunitinib—Fatigue—Doxorubicin—testicular cancer	1.51e-05	0.000217	CcSEcCtD
Sunitinib—Pain—Doxorubicin—testicular cancer	1.5e-05	0.000215	CcSEcCtD
Sunitinib—Constipation—Doxorubicin—testicular cancer	1.5e-05	0.000215	CcSEcCtD
Sunitinib—Abdominal pain—Epirubicin—testicular cancer	1.5e-05	0.000215	CcSEcCtD
Sunitinib—Body temperature increased—Epirubicin—testicular cancer	1.5e-05	0.000215	CcSEcCtD
Sunitinib—Hypersensitivity—Methotrexate—testicular cancer	1.49e-05	0.000214	CcSEcCtD
Sunitinib—Asthenia—Methotrexate—testicular cancer	1.45e-05	0.000208	CcSEcCtD
Sunitinib—Gastrointestinal pain—Doxorubicin—testicular cancer	1.43e-05	0.000206	CcSEcCtD
Sunitinib—Pruritus—Methotrexate—testicular cancer	1.43e-05	0.000205	CcSEcCtD
Sunitinib—Hypersensitivity—Epirubicin—testicular cancer	1.4e-05	0.0002	CcSEcCtD
Sunitinib—Abdominal pain—Doxorubicin—testicular cancer	1.39e-05	0.000199	CcSEcCtD
Sunitinib—Body temperature increased—Doxorubicin—testicular cancer	1.39e-05	0.000199	CcSEcCtD
Sunitinib—Diarrhoea—Methotrexate—testicular cancer	1.39e-05	0.000199	CcSEcCtD
Sunitinib—Asthenia—Epirubicin—testicular cancer	1.36e-05	0.000195	CcSEcCtD
Sunitinib—Pruritus—Epirubicin—testicular cancer	1.34e-05	0.000192	CcSEcCtD
Sunitinib—Dizziness—Methotrexate—testicular cancer	1.34e-05	0.000192	CcSEcCtD
Sunitinib—Diarrhoea—Epirubicin—testicular cancer	1.3e-05	0.000186	CcSEcCtD
Sunitinib—Hypersensitivity—Doxorubicin—testicular cancer	1.29e-05	0.000185	CcSEcCtD
Sunitinib—Vomiting—Methotrexate—testicular cancer	1.29e-05	0.000185	CcSEcCtD
Sunitinib—Rash—Methotrexate—testicular cancer	1.28e-05	0.000183	CcSEcCtD
Sunitinib—Dermatitis—Methotrexate—testicular cancer	1.28e-05	0.000183	CcSEcCtD
Sunitinib—Headache—Methotrexate—testicular cancer	1.27e-05	0.000182	CcSEcCtD
Sunitinib—Asthenia—Doxorubicin—testicular cancer	1.26e-05	0.00018	CcSEcCtD
Sunitinib—Dizziness—Epirubicin—testicular cancer	1.25e-05	0.00018	CcSEcCtD
Sunitinib—Pruritus—Doxorubicin—testicular cancer	1.24e-05	0.000178	CcSEcCtD
Sunitinib—Vomiting—Epirubicin—testicular cancer	1.2e-05	0.000173	CcSEcCtD
Sunitinib—Nausea—Methotrexate—testicular cancer	1.2e-05	0.000172	CcSEcCtD
Sunitinib—Diarrhoea—Doxorubicin—testicular cancer	1.2e-05	0.000172	CcSEcCtD
Sunitinib—Rash—Epirubicin—testicular cancer	1.19e-05	0.000171	CcSEcCtD
Sunitinib—Dermatitis—Epirubicin—testicular cancer	1.19e-05	0.000171	CcSEcCtD
Sunitinib—Headache—Epirubicin—testicular cancer	1.19e-05	0.00017	CcSEcCtD
Sunitinib—Dizziness—Doxorubicin—testicular cancer	1.16e-05	0.000166	CcSEcCtD
Sunitinib—Nausea—Epirubicin—testicular cancer	1.13e-05	0.000161	CcSEcCtD
Sunitinib—Vomiting—Doxorubicin—testicular cancer	1.11e-05	0.00016	CcSEcCtD
Sunitinib—Rash—Doxorubicin—testicular cancer	1.11e-05	0.000158	CcSEcCtD
Sunitinib—Dermatitis—Doxorubicin—testicular cancer	1.1e-05	0.000158	CcSEcCtD
Sunitinib—ABCB1—lymph node—testicular cancer	1.1e-05	0.000173	CbGeAlD
Sunitinib—Headache—Doxorubicin—testicular cancer	1.1e-05	0.000157	CcSEcCtD
Sunitinib—Nausea—Doxorubicin—testicular cancer	1.04e-05	0.000149	CcSEcCtD
Sunitinib—MAP3K3—Immune System—KIT—testicular cancer	6.9e-06	0.000122	CbGpPWpGaD
Sunitinib—MAP3K7—Innate Immune System—KIT—testicular cancer	6.88e-06	0.000121	CbGpPWpGaD
Sunitinib—CSNK1E—Signaling Pathways—STK11—testicular cancer	6.87e-06	0.000121	CbGpPWpGaD
Sunitinib—FGFR1—Adaptive Immune System—FGFR3—testicular cancer	6.83e-06	0.00012	CbGpPWpGaD
Sunitinib—PDGFRA—Adaptive Immune System—FGFR3—testicular cancer	6.81e-06	0.00012	CbGpPWpGaD
Sunitinib—RPS6KA3—Immune System—FGFR3—testicular cancer	6.79e-06	0.00012	CbGpPWpGaD
Sunitinib—CSNK1E—Disease—FGFR3—testicular cancer	6.75e-06	0.000119	CbGpPWpGaD
Sunitinib—CSNK2A1—Signaling Pathways—KIT—testicular cancer	6.73e-06	0.000119	CbGpPWpGaD
Sunitinib—FLT4—Signaling Pathways—KIT—testicular cancer	6.73e-06	0.000119	CbGpPWpGaD
Sunitinib—FGFR2—Adaptive Immune System—KIT—testicular cancer	6.73e-06	0.000119	CbGpPWpGaD
Sunitinib—MAP3K7—Adaptive Immune System—KIT—testicular cancer	6.61e-06	0.000117	CbGpPWpGaD
Sunitinib—YES1—Immune System—KITLG—testicular cancer	6.58e-06	0.000116	CbGpPWpGaD
Sunitinib—PRKAA2—Signaling Pathways—FGFR3—testicular cancer	6.56e-06	0.000116	CbGpPWpGaD
Sunitinib—FGFR1—Developmental Biology—MMP2—testicular cancer	6.55e-06	0.000116	CbGpPWpGaD
Sunitinib—MAP2K2—Innate Immune System—FGFR3—testicular cancer	6.55e-06	0.000115	CbGpPWpGaD
Sunitinib—FGFR1—Innate Immune System—KIT—testicular cancer	6.53e-06	0.000115	CbGpPWpGaD
Sunitinib—PAK3—Signaling Pathways—KIT—testicular cancer	6.53e-06	0.000115	CbGpPWpGaD
Sunitinib—PDGFRA—Innate Immune System—KIT—testicular cancer	6.51e-06	0.000115	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—H2AFZ—testicular cancer	6.48e-06	0.000114	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—STK11—testicular cancer	6.44e-06	0.000114	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—H2AFZ—testicular cancer	6.42e-06	0.000113	CbGpPWpGaD
Sunitinib—IRAK4—Immune System—KIT—testicular cancer	6.41e-06	0.000113	CbGpPWpGaD
Sunitinib—PDGFRB—Innate Immune System—FGFR3—testicular cancer	6.39e-06	0.000113	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—STK11—testicular cancer	6.39e-06	0.000113	CbGpPWpGaD
Sunitinib—CSNK1E—Signaling Pathways—KITLG—testicular cancer	6.36e-06	0.000112	CbGpPWpGaD
Sunitinib—FGFR1—Adaptive Immune System—KIT—testicular cancer	6.27e-06	0.000111	CbGpPWpGaD
Sunitinib—PDGFRA—Adaptive Immune System—KIT—testicular cancer	6.25e-06	0.00011	CbGpPWpGaD
Sunitinib—IRAK1—Immune System—KITLG—testicular cancer	6.24e-06	0.00011	CbGpPWpGaD
Sunitinib—RPS6KA3—Immune System—KIT—testicular cancer	6.24e-06	0.00011	CbGpPWpGaD
Sunitinib—PTK2B—Immune System—FGFR3—testicular cancer	6.22e-06	0.00011	CbGpPWpGaD
Sunitinib—RPS6KA5—Signaling Pathways—FGFR3—testicular cancer	6.2e-06	0.000109	CbGpPWpGaD
Sunitinib—CSNK1E—Disease—KIT—testicular cancer	6.19e-06	0.000109	CbGpPWpGaD
Sunitinib—FYN—Innate Immune System—FGFR3—testicular cancer	6.16e-06	0.000109	CbGpPWpGaD
Sunitinib—RPS6KA2—Signaling Pathways—FGFR3—testicular cancer	6.14e-06	0.000108	CbGpPWpGaD
Sunitinib—PDGFRB—Adaptive Immune System—FGFR3—testicular cancer	6.14e-06	0.000108	CbGpPWpGaD
Sunitinib—MAP2K1—Innate Immune System—FGFR3—testicular cancer	6.13e-06	0.000108	CbGpPWpGaD
Sunitinib—TYK2—Disease—H2AFZ—testicular cancer	6.08e-06	0.000107	CbGpPWpGaD
Sunitinib—BLK—Immune System—FGFR3—testicular cancer	6.07e-06	0.000107	CbGpPWpGaD
Sunitinib—TYK2—Immune System—KITLG—testicular cancer	6.05e-06	0.000107	CbGpPWpGaD
Sunitinib—FGR—Immune System—FGFR3—testicular cancer	6.05e-06	0.000107	CbGpPWpGaD
Sunitinib—MAP2K2—Developmental Biology—MMP2—testicular cancer	6.03e-06	0.000106	CbGpPWpGaD
Sunitinib—PRKAA2—Signaling Pathways—KIT—testicular cancer	6.02e-06	0.000106	CbGpPWpGaD
Sunitinib—MAP2K2—Innate Immune System—KIT—testicular cancer	6.01e-06	0.000106	CbGpPWpGaD
Sunitinib—FGFR2—Disease—H2AFZ—testicular cancer	6e-06	0.000106	CbGpPWpGaD
Sunitinib—FGFR2—Immune System—KITLG—testicular cancer	5.98e-06	0.000105	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—KITLG—testicular cancer	5.96e-06	0.000105	CbGpPWpGaD
Sunitinib—FYN—Adaptive Immune System—FGFR3—testicular cancer	5.91e-06	0.000104	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—KITLG—testicular cancer	5.91e-06	0.000104	CbGpPWpGaD
Sunitinib—KIT—Disease—H2AFZ—testicular cancer	5.89e-06	0.000104	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—H2AFZ—testicular cancer	5.89e-06	0.000104	CbGpPWpGaD
Sunitinib—KIT—Immune System—KITLG—testicular cancer	5.87e-06	0.000104	CbGpPWpGaD
Sunitinib—MAP3K7—Immune System—KITLG—testicular cancer	5.87e-06	0.000104	CbGpPWpGaD
Sunitinib—PDGFRB—Innate Immune System—KIT—testicular cancer	5.87e-06	0.000103	CbGpPWpGaD
Sunitinib—JAK2—Innate Immune System—FGFR3—testicular cancer	5.85e-06	0.000103	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—STK11—testicular cancer	5.85e-06	0.000103	CbGpPWpGaD
Sunitinib—CSNK1A1—Signaling Pathways—FGFR3—testicular cancer	5.85e-06	0.000103	CbGpPWpGaD
Sunitinib—PTK2B—Immune System—KIT—testicular cancer	5.71e-06	0.000101	CbGpPWpGaD
Sunitinib—RPS6KA5—Signaling Pathways—KIT—testicular cancer	5.69e-06	0.0001	CbGpPWpGaD
Sunitinib—FYN—Developmental Biology—MMP2—testicular cancer	5.67e-06	0.0001	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—H2AFZ—testicular cancer	5.67e-06	0.0001	CbGpPWpGaD
Sunitinib—FYN—Innate Immune System—KIT—testicular cancer	5.66e-06	9.97e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Developmental Biology—MMP2—testicular cancer	5.64e-06	9.95e-05	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—STK11—testicular cancer	5.64e-06	9.94e-05	CbGpPWpGaD
Sunitinib—RPS6KA2—Signaling Pathways—KIT—testicular cancer	5.63e-06	9.94e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Adaptive Immune System—KIT—testicular cancer	5.63e-06	9.94e-05	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—H2AFZ—testicular cancer	5.63e-06	9.93e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Innate Immune System—KIT—testicular cancer	5.62e-06	9.92e-05	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—STK11—testicular cancer	5.6e-06	9.88e-05	CbGpPWpGaD
Sunitinib—FGFR1—Disease—H2AFZ—testicular cancer	5.59e-06	9.86e-05	CbGpPWpGaD
Sunitinib—TYK2—Disease—KITLG—testicular cancer	5.59e-06	9.86e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—H2AFZ—testicular cancer	5.58e-06	9.84e-05	CbGpPWpGaD
Sunitinib—BLK—Immune System—KIT—testicular cancer	5.58e-06	9.84e-05	CbGpPWpGaD
Sunitinib—FGFR1—Immune System—KITLG—testicular cancer	5.57e-06	9.83e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Immune System—KITLG—testicular cancer	5.56e-06	9.8e-05	CbGpPWpGaD
Sunitinib—FGR—Immune System—KIT—testicular cancer	5.56e-06	9.8e-05	CbGpPWpGaD
Sunitinib—FGFR2—Disease—KITLG—testicular cancer	5.52e-06	9.74e-05	CbGpPWpGaD
Sunitinib—RPS6KA1—Signaling Pathways—FGFR3—testicular cancer	5.51e-06	9.72e-05	CbGpPWpGaD
Sunitinib—FLT1—Signaling Pathways—FGFR3—testicular cancer	5.47e-06	9.65e-05	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—H2AFZ—testicular cancer	5.46e-06	9.63e-05	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—H2AFZ—testicular cancer	5.46e-06	9.63e-05	CbGpPWpGaD
Sunitinib—FYN—Adaptive Immune System—KIT—testicular cancer	5.43e-06	9.58e-05	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—STK11—testicular cancer	5.43e-06	9.58e-05	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—STK11—testicular cancer	5.43e-06	9.58e-05	CbGpPWpGaD
Sunitinib—KIT—Disease—KITLG—testicular cancer	5.42e-06	9.56e-05	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—KITLG—testicular cancer	5.41e-06	9.55e-05	CbGpPWpGaD
Sunitinib—JAK2—Developmental Biology—MMP2—testicular cancer	5.39e-06	9.51e-05	CbGpPWpGaD
Sunitinib—JAK2—Innate Immune System—KIT—testicular cancer	5.38e-06	9.48e-05	CbGpPWpGaD
Sunitinib—CSNK1A1—Signaling Pathways—KIT—testicular cancer	5.37e-06	9.47e-05	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—H2AFZ—testicular cancer	5.32e-06	9.39e-05	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—STK11—testicular cancer	5.29e-06	9.33e-05	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—KITLG—testicular cancer	5.22e-06	9.2e-05	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—KITLG—testicular cancer	5.18e-06	9.14e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—H2AFZ—testicular cancer	5.15e-06	9.08e-05	CbGpPWpGaD
Sunitinib—FGFR1—Disease—KITLG—testicular cancer	5.15e-06	9.07e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—KITLG—testicular cancer	5.13e-06	9.05e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—KITLG—testicular cancer	5.13e-06	9.05e-05	CbGpPWpGaD
Sunitinib—RPS6KA1—Signaling Pathways—KIT—testicular cancer	5.06e-06	8.93e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—H2AFZ—testicular cancer	5.03e-06	8.86e-05	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—KITLG—testicular cancer	5.02e-06	8.86e-05	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—KITLG—testicular cancer	5.02e-06	8.86e-05	CbGpPWpGaD
Sunitinib—FLT1—Signaling Pathways—KIT—testicular cancer	5.02e-06	8.86e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—KITLG—testicular cancer	5.01e-06	8.83e-05	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—KITLG—testicular cancer	4.9e-06	8.64e-05	CbGpPWpGaD
Sunitinib—YES1—Immune System—FGFR3—testicular cancer	4.89e-06	8.62e-05	CbGpPWpGaD
Sunitinib—FYN—Disease—H2AFZ—testicular cancer	4.84e-06	8.54e-05	CbGpPWpGaD
Sunitinib—FYN—Immune System—KITLG—testicular cancer	4.83e-06	8.51e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—H2AFZ—testicular cancer	4.82e-06	8.5e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—KITLG—testicular cancer	4.8e-06	8.47e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—KITLG—testicular cancer	4.74e-06	8.36e-05	CbGpPWpGaD
Sunitinib—CSNK1E—Signaling Pathways—FGFR3—testicular cancer	4.72e-06	8.33e-05	CbGpPWpGaD
Sunitinib—IRAK1—Immune System—FGFR3—testicular cancer	4.64e-06	8.17e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—KITLG—testicular cancer	4.62e-06	8.15e-05	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—H2AFZ—testicular cancer	4.62e-06	8.15e-05	CbGpPWpGaD
Sunitinib—JAK2—Disease—H2AFZ—testicular cancer	4.6e-06	8.12e-05	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—STK11—testicular cancer	4.59e-06	8.1e-05	CbGpPWpGaD
Sunitinib—JAK2—Immune System—KITLG—testicular cancer	4.59e-06	8.09e-05	CbGpPWpGaD
Sunitinib—TYK2—Immune System—FGFR3—testicular cancer	4.5e-06	7.94e-05	CbGpPWpGaD
Sunitinib—YES1—Immune System—KIT—testicular cancer	4.49e-06	7.91e-05	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—HPGDS—testicular cancer	4.48e-06	7.9e-05	CbGpPWpGaD
Sunitinib—FYN—Disease—KITLG—testicular cancer	4.46e-06	7.86e-05	CbGpPWpGaD
Sunitinib—FGFR2—Immune System—FGFR3—testicular cancer	4.44e-06	7.84e-05	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—HPGDS—testicular cancer	4.44e-06	7.83e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—KITLG—testicular cancer	4.43e-06	7.82e-05	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—FGFR3—testicular cancer	4.43e-06	7.82e-05	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—FGFR3—testicular cancer	4.39e-06	7.75e-05	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—H2AFZ—testicular cancer	4.38e-06	7.73e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Immune System—FGFR3—testicular cancer	4.36e-06	7.7e-05	CbGpPWpGaD
Sunitinib—KIT—Immune System—FGFR3—testicular cancer	4.36e-06	7.7e-05	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—STK11—testicular cancer	4.36e-06	7.69e-05	CbGpPWpGaD
Sunitinib—CSNK1E—Signaling Pathways—KIT—testicular cancer	4.34e-06	7.65e-05	CbGpPWpGaD
Sunitinib—IRAK1—Immune System—KIT—testicular cancer	4.26e-06	7.51e-05	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—H2AFZ—testicular cancer	4.25e-06	7.5e-05	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—KITLG—testicular cancer	4.25e-06	7.5e-05	CbGpPWpGaD
Sunitinib—JAK2—Disease—KITLG—testicular cancer	4.24e-06	7.47e-05	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—STK11—testicular cancer	4.23e-06	7.46e-05	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—H2AFZ—testicular cancer	4.2e-06	7.41e-05	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—STK11—testicular cancer	4.18e-06	7.37e-05	CbGpPWpGaD
Sunitinib—TYK2—Disease—FGFR3—testicular cancer	4.15e-06	7.33e-05	CbGpPWpGaD
Sunitinib—FGFR1—Immune System—FGFR3—testicular cancer	4.14e-06	7.3e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Immune System—FGFR3—testicular cancer	4.13e-06	7.29e-05	CbGpPWpGaD
Sunitinib—TYK2—Immune System—KIT—testicular cancer	4.13e-06	7.29e-05	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—H2AFZ—testicular cancer	4.13e-06	7.28e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—H2AFZ—testicular cancer	4.13e-06	7.28e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—STK11—testicular cancer	4.1e-06	7.24e-05	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—STK11—testicular cancer	4.1e-06	7.24e-05	CbGpPWpGaD
Sunitinib—FGFR2—Disease—FGFR3—testicular cancer	4.1e-06	7.24e-05	CbGpPWpGaD
Sunitinib—FGFR2—Immune System—KIT—testicular cancer	4.08e-06	7.2e-05	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—KIT—testicular cancer	4.07e-06	7.18e-05	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—KITLG—testicular cancer	4.03e-06	7.11e-05	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—KIT—testicular cancer	4.03e-06	7.11e-05	CbGpPWpGaD
Sunitinib—KIT—Disease—FGFR3—testicular cancer	4.03e-06	7.11e-05	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—FGFR3—testicular cancer	4.02e-06	7.1e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Immune System—KIT—testicular cancer	4.01e-06	7.07e-05	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—H2AFZ—testicular cancer	3.92e-06	6.91e-05	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—KITLG—testicular cancer	3.91e-06	6.9e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—H2AFZ—testicular cancer	3.91e-06	6.89e-05	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—STK11—testicular cancer	3.89e-06	6.87e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—STK11—testicular cancer	3.88e-06	6.85e-05	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—FGFR3—testicular cancer	3.88e-06	6.84e-05	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—KITLG—testicular cancer	3.87e-06	6.82e-05	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—FGFR3—testicular cancer	3.85e-06	6.79e-05	CbGpPWpGaD
Sunitinib—FGFR1—Disease—FGFR3—testicular cancer	3.82e-06	6.74e-05	CbGpPWpGaD
Sunitinib—TYK2—Disease—KIT—testicular cancer	3.81e-06	6.73e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—FGFR3—testicular cancer	3.81e-06	6.73e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—FGFR3—testicular cancer	3.81e-06	6.73e-05	CbGpPWpGaD
Sunitinib—FGFR1—Immune System—KIT—testicular cancer	3.8e-06	6.71e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—KITLG—testicular cancer	3.8e-06	6.7e-05	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—KITLG—testicular cancer	3.8e-06	6.7e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Immune System—KIT—testicular cancer	3.79e-06	6.69e-05	CbGpPWpGaD
Sunitinib—FGFR2—Disease—KIT—testicular cancer	3.77e-06	6.64e-05	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—FGFR3—testicular cancer	3.73e-06	6.59e-05	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—FGFR3—testicular cancer	3.73e-06	6.59e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—FGFR3—testicular cancer	3.72e-06	6.56e-05	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—KIT—testicular cancer	3.69e-06	6.52e-05	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—FGFR3—testicular cancer	3.64e-06	6.42e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—H2AFZ—testicular cancer	3.61e-06	6.36e-05	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—KITLG—testicular cancer	3.6e-06	6.35e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—KITLG—testicular cancer	3.59e-06	6.34e-05	CbGpPWpGaD
Sunitinib—FYN—Immune System—FGFR3—testicular cancer	3.59e-06	6.33e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—STK11—testicular cancer	3.59e-06	6.32e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—FGFR3—testicular cancer	3.57e-06	6.29e-05	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—KIT—testicular cancer	3.56e-06	6.28e-05	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—KIT—testicular cancer	3.54e-06	6.24e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—FGFR3—testicular cancer	3.52e-06	6.21e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—H2AFZ—testicular cancer	3.52e-06	6.21e-05	CbGpPWpGaD
Sunitinib—FGFR1—Disease—KIT—testicular cancer	3.51e-06	6.19e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—KIT—testicular cancer	3.5e-06	6.18e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—KIT—testicular cancer	3.5e-06	6.18e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—STK11—testicular cancer	3.5e-06	6.17e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—FGFR3—testicular cancer	3.44e-06	6.06e-05	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—KIT—testicular cancer	3.43e-06	6.05e-05	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—KIT—testicular cancer	3.43e-06	6.05e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—KIT—testicular cancer	3.42e-06	6.03e-05	CbGpPWpGaD
Sunitinib—JAK2—Immune System—FGFR3—testicular cancer	3.41e-06	6.01e-05	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—H2AFZ—testicular cancer	3.39e-06	5.98e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—H2AFZ—testicular cancer	3.37e-06	5.95e-05	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—STK11—testicular cancer	3.37e-06	5.95e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—STK11—testicular cancer	3.35e-06	5.92e-05	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—KIT—testicular cancer	3.34e-06	5.89e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—KITLG—testicular cancer	3.32e-06	5.85e-05	CbGpPWpGaD
Sunitinib—FYN—Disease—FGFR3—testicular cancer	3.31e-06	5.84e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—FGFR3—testicular cancer	3.29e-06	5.81e-05	CbGpPWpGaD
Sunitinib—FYN—Immune System—KIT—testicular cancer	3.29e-06	5.81e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—KIT—testicular cancer	3.28e-06	5.78e-05	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—STK11—testicular cancer	3.25e-06	5.74e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—KITLG—testicular cancer	3.24e-06	5.71e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—KIT—testicular cancer	3.23e-06	5.7e-05	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—STK11—testicular cancer	3.22e-06	5.69e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—H2AFZ—testicular cancer	3.22e-06	5.69e-05	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—HPGDS—testicular cancer	3.21e-06	5.66e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—STK11—testicular cancer	3.21e-06	5.65e-05	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—FGFR3—testicular cancer	3.16e-06	5.57e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—KIT—testicular cancer	3.15e-06	5.56e-05	CbGpPWpGaD
Sunitinib—JAK2—Disease—FGFR3—testicular cancer	3.15e-06	5.55e-05	CbGpPWpGaD
Sunitinib—JAK2—Immune System—KIT—testicular cancer	3.13e-06	5.52e-05	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—KITLG—testicular cancer	3.12e-06	5.5e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—KITLG—testicular cancer	3.1e-06	5.47e-05	CbGpPWpGaD
Sunitinib—FYN—Disease—KIT—testicular cancer	3.04e-06	5.36e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—KIT—testicular cancer	3.02e-06	5.33e-05	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—FGFR3—testicular cancer	3e-06	5.29e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—KITLG—testicular cancer	2.97e-06	5.23e-05	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—FGFR3—testicular cancer	2.91e-06	5.13e-05	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—KIT—testicular cancer	2.9e-06	5.12e-05	CbGpPWpGaD
Sunitinib—JAK2—Disease—KIT—testicular cancer	2.89e-06	5.1e-05	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—FGFR3—testicular cancer	2.87e-06	5.07e-05	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—FGFR3—testicular cancer	2.82e-06	4.98e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—FGFR3—testicular cancer	2.82e-06	4.98e-05	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—KIT—testicular cancer	2.75e-06	4.85e-05	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—FGFR3—testicular cancer	2.68e-06	4.72e-05	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—KIT—testicular cancer	2.67e-06	4.71e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—FGFR3—testicular cancer	2.67e-06	4.71e-05	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—KIT—testicular cancer	2.64e-06	4.65e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—KIT—testicular cancer	2.59e-06	4.57e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—FGFR3—testicular cancer	2.47e-06	4.35e-05	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—KIT—testicular cancer	2.46e-06	4.34e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—KIT—testicular cancer	2.45e-06	4.32e-05	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—HPGDS—testicular cancer	2.42e-06	4.27e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—FGFR3—testicular cancer	2.41e-06	4.24e-05	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—STK11—testicular cancer	2.33e-06	4.11e-05	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—FGFR3—testicular cancer	2.32e-06	4.09e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—FGFR3—testicular cancer	2.31e-06	4.07e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—KIT—testicular cancer	2.26e-06	3.99e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—KIT—testicular cancer	2.21e-06	3.9e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—FGFR3—testicular cancer	2.2e-06	3.89e-05	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—KIT—testicular cancer	2.13e-06	3.76e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—KIT—testicular cancer	2.12e-06	3.74e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—KIT—testicular cancer	2.02e-06	3.57e-05	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—STK11—testicular cancer	1.76e-06	3.1e-05	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—HPGDS—testicular cancer	1.49e-06	2.63e-05	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—STK11—testicular cancer	1.08e-06	1.91e-05	CbGpPWpGaD
